251
|
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol 2010; 257:1524-32. [PMID: 20411272 DOI: 10.1007/s00415-010-5566-8] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2010] [Accepted: 04/07/2010] [Indexed: 10/19/2022]
Abstract
Studies of late stages of Parkinson's disease (LS-PD) are limited. To provide an adequate health plan for patients in these most advanced stages, accurate information on their clinical condition is necessary. We characterize clinical features and medication use of LS-PD. A cross-sectional study of LS-PD stage 4 or 5 of Hoehn and Yahr during on states is presented in this paper. Demographics, clinical features and medication data were obtained using a structured questionnaire and physical examination. Patients were asked to grade the perceived impact of symptoms on their health status. Fifty patients (mean age 74.1 years and mean disease duration 17.9 years) were studied. Severe akinetic symmetric parkinsonism was present in most, with negligible rigidity and tremor, and most patients were wheelchair-bound. Severe postural instability and freezing of gait, causing frequent falls and fractures, and prominent dysarthria and dysphagia dominated the motor syndrome. Levodopa remained effective in most patients in relieving motor symptoms including tremor. Motor fluctuations and dyskinesias were present in 78 and 62% of patients, respectively, but were not perceived as disabling. All had neuropsychiatric and dysautonomic symptoms. Visual hallucinations were present in 44%, depression in 62% and dementia in 50%. Lack of tremor (p < 0.01) and absence of depression (p < 0.01) were independently associated with dementia (R(2) = 45%). Symptoms causing greatest impact on perceived health status were falls, gait unsteadiness, urinary dysfunction and sweats. Motor and non-motor non-levodopa responsive problems were frequent and the main cause of disability. Fluctuations and dyskinesias were frequent though not disabling. Dementia is not unavoidable in these very late stages.
Collapse
|
252
|
Montel S, Bungener C. Coping et qualité de vie dans la sclérose en plaques et la maladie de Parkinson : une réflexion clinique. ANNALES MEDICO-PSYCHOLOGIQUES 2010. [DOI: 10.1016/j.amp.2008.04.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
253
|
Abstract
Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These behaviors usually do not occur in the presence of the physician and are therefore difficult to rate. Further, because of their bizarre nature, hallucinations are frequently underreported by patients, and caregivers are often unaware of them until they become problematic. A number of scales have been developed for rating these behaviors, most of them borrowed or adapted from assessment tools used in other psychotic disorders like schizophrenia. In the latter disorders, however, hallucinations and psychosis are phenomenologically different than the typical hallucinations of Parkinson's disease. The Movement Disorder Society Task Force on Parkinson's Disease Rating Scales has completed a systematic critique of scales used in clinical trials focusing on hallucinations and psychosis. In this critique, the following scales met the criteria to be classified as Recommended: Neuropsychiatric Inventory, Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale, and Schedule for Assessment of Positive Symptoms. However, the Task Force felt that each of these scales has significant weaknesses and is insufficient to be considered a definitive rating tool. The Task Force officially recommended the development of a new scale to assess hallucinations and psychosis in Parkinson's disease. This effort is now ongoing with official endorsement by the Movement Disorder Society.
Collapse
|
254
|
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol 2010; 257:1073-82. [PMID: 20140443 DOI: 10.1007/s00415-010-5465-z] [Citation(s) in RCA: 177] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2009] [Revised: 12/11/2009] [Accepted: 01/11/2010] [Indexed: 02/02/2023]
Abstract
Neuropsychiatric symptoms (NPS) of Parkinson's disease (PD) are of growing diagnostic and therapeutic importance. Data on their prevalence and characteristics have been primarily derived from highly selective clinical populations. We have conducted a national study in the outpatient care sector to provide a fuller characterization of the frequency of dementia, depression, and other NPS in PD outpatients. We also examined associations with biosocial and neurological variables. A nationwide representative sample of 1,449 PD outpatients was examined with a standardized clinical interview. PD severity was rated with the Hoehn and Yahr (HY) scale and the Unified Parkinson's Disease Rating Scale. Depression was measured with the Montgomery-Asberg Depression Rating Scale. Cognitive impairment and dementia were assessed with the Mini-Mental State Exam and according to diagnostic criteria. Logistic regression analyses were used to investigate associations. At least one NPS occurred in 71% of all patients with PD. The estimated prevalences (ranges) by age group and HY-stage were: depression, 25% (13.2-47.9%), dementia, 29% (12.2-59.4%), and psychotic syndromes, 12.7% (3.1-40.9%). Other frequent complications were sleep disturbances (49%) and anxiety (20%). Depression was associated with gender but not with age. Dementia was associated with age. The rates and comorbidity of depression and dementia were driven by PD severity. NPS were highly prevalent in our comprehensive patient sample, largely representative of management problems occurring in an outpatient setting. PD outpatients are at an increased risk for all neuropsychiatric conditions, increasing with PD severity but not with age or age of onset (except dementia), revealing challenging symptom patterns.
Collapse
Affiliation(s)
- Oliver Riedel
- Institute of Clinical Psychology and Psychotherapy, Technical University of Dresden, Chemnitzer Strasse 46, Dresden, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
255
|
Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. J Neural Transm (Vienna) 2010; 117:353-67. [PMID: 20119649 DOI: 10.1007/s00702-010-0370-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2009] [Accepted: 01/10/2010] [Indexed: 12/13/2022]
Abstract
Older adults suffering from Parkinson's disease (PD) frequently present with an additional form of severe neurodegenerative and/or vascular pathology. Findings of differential clinical manifestations of cognitive impairment, depending on presence and nature of such coexisting brain pathology, raise the question for neuropsychological procedures that are capable not only of distinguishing between non-demented PD patients and patients with Parkinson-associated dementia (PDD), but also of detecting other types of cognitive decline, most likely Alzheimer's disease (AD) or vascular dementia (VD), superimposing PD. The aim of this article is to review the literature on neuropsychological processes at risk in developing PDD, to introduce comorbid causes of cognitive decline in the presence of PD, to discuss the scope of the "cortical versus subcortical dementia"-concept in view of its capability of differentiating dementias, and to scrutinize existing diagnostic criteria concerning the toleration of comorbidity. Additionally, we derive an evidence-based neuropsychological diagnostic procedure for assessing PDD under special consideration of these comorbid aspects.
Collapse
|
256
|
García-Ramos R, Villanueva C, del Val J, Matías-Guíu J. Apatía en la enfermedad de Parkinson. Neurologia 2010. [DOI: 10.1016/s0213-4853(10)70021-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
257
|
García-Ramos R, Villanueva C, del Val J, Matías-Guíu J. Apathy in Parkinson's disease. NEUROLOGÍA (ENGLISH EDITION) 2010. [DOI: 10.1016/s2173-5808(10)70007-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
|
258
|
Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia. ACTA ACUST UNITED AC 2009; 40:149-55. [DOI: 10.1007/s11055-009-9244-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
259
|
Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother 2009; 10:2407-14. [PMID: 19663744 DOI: 10.1517/14656560903200659] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Recent emerging data regarding the safety and tolerability of atypical antipsychotics in elderly patients with dementia have called into question common prescribing practices. Although the lifetime risk of developing significant psychopathology in dementia patients approaches nearly 100%, treatment options remain scant and controversial. Millions of people are suffering the consequences of these debilitating dementias. Yet the lack of regulatory approval or even recognition of the problem creates a dilemma for clinicians in practice who are trying to care for severely ill patients. There are data indicating that certain behavioral features can be treated successfully with atypical antipsychotics, offset by a high rate of adversity. This does not lead to the simple conclusion that they should never be used, since the alternatives are either fraught with the same shortcomings or actually lack evidence of benefit altogether. Further, it is not realistic to assume that nonpharmacological approaches, although preferred, will always carry the day. Since we do not have the evidence to define best practice for treating psychopathology, we are forced to make the most of the data we have and exercise best judgment about risk and benefit on a case-by-case basis.
Collapse
Affiliation(s)
- Anna D Burke
- Banner Alzheimer's Institute, Phoenix, AZ 85006, USA.
| | | |
Collapse
|
260
|
Mavandadi S, Nazem S, Ten Have TR, Siderowf AD, Duda JE, Stern MB, Weintraub D. Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. Am J Geriatr Psychiatry 2009; 17:986-95. [PMID: 19855199 PMCID: PMC2848973 DOI: 10.1097/jgp.0b013e3181b215ec] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVES A range of psychiatric symptoms and cognitive deficits occur in Parkinson disease (PD), and symptom overlap and comorbidity complicate the classification of nonmotor symptoms. The objective of this study was to use analytic-based approaches to classify psychiatric and cognitive symptoms in PD. DESIGN Cross-sectional evaluation of a convenience sample of patients in specialty care. SETTING Two outpatient movement disorders centers at the University of Pennsylvania and Philadelphia Veterans Affairs Medical Center. PARTICIPANTS One hundred seventy-seven patients with mild-moderate idiopathic PD and without significant global cognitive impairment. MEASUREMENTS Subjects were assessed with an extensive psychiatric, neuropsychological, and neurological battery. Latent class analysis (LCA) was used to statistically delineate group-level symptom profiles across measures of psychiatric and cognitive functioning. Predictors of class membership were also examined. RESULTS Results from the LCA indicated that a four-class solution best fit the data. The 32.3% of the sample had good psychiatric and normal cognitive functioning, 17.5% had significant psychiatric comorbidity but normal cognition, 26.0% had few psychiatric symptoms but had poorer cognitive functioning across a range of cognitive domains, and 24.3% had both significant psychiatric comorbidity and poorer cognitive functioning. Age, disease severity, and medication use predicted class membership. CONCLUSIONS LCA delineates four classes of patients in mild-moderate PD, three of which experience significant nonmotor impairments and comprise over two thirds of patients. Neuropsychiatric symptoms and cognitive deficits follow distinct patterns in PD, and further study is needed to determine whether these classes are generalizable, stable, predict function, quality of life, and long-term outcomes and are amenable to treatment at a class level.
Collapse
Affiliation(s)
- Shahrzad Mavandadi
- Mental Illness Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, USA
| | - Sarra Nazem
- Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
| | - Thomas R. Ten Have
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA
| | | | - John E. Duda
- Department of Neurology, University of Pennsylvania, Philadelphia, USA
- Parkinson’s Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, USA
| | - Matthew B. Stern
- Department of Neurology, University of Pennsylvania, Philadelphia, USA
- Parkinson’s Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, USA
| | - Daniel Weintraub
- Mental Illness Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, USA
- Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
- Department of Neurology, University of Pennsylvania, Philadelphia, USA
- Parkinson’s Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, USA
| |
Collapse
|
261
|
Siri C, Cilia R, De Gaspari D, Villa F, Goldwurm S, Marco C, Pezzoli G, Antonini A. Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci 2009; 31:35-40. [PMID: 19806311 DOI: 10.1007/s10072-009-0165-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2009] [Accepted: 09/22/2009] [Indexed: 01/20/2023]
Abstract
The frequency of psychopathological symptoms in patients with Parkinson's disease (PD) is often underestimated because of the lack of comprehensive evaluation tools. A total of 486 consecutive non-demented PD patients completed the Symptom Checklist 90 Revised (SCL-90R) self-reported questionnaire, a validated tool for the assessment of psychopathological symptoms on nine dimensions. Somatization, depression, anxiety and obsessive-compulsive behaviors were reported by nearly half of the PD patients. They were more likely to occur in females. Disease-related factors such as duration, severity and daily dosages, but not type of dopaminergic medications, were associated with the occurrence of these symptoms. Psychopathological features are frequent in PD and their occurrence is underlined by disease-related factors.
Collapse
Affiliation(s)
- Chiara Siri
- Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20123, Milan, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
262
|
Stella F, Banzato CEM, Quagliato EMAB, Viana MA, Christofoletti G. Psychopathological features in patients with Parkinson's disease and related caregivers' burden. Int J Geriatr Psychiatry 2009; 24:1158-65. [PMID: 19319995 DOI: 10.1002/gps.2240] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND Along with classical motor disorders in Parkinson's disease (PD), psychopathological features frequently co-occur, which may increase the caregiver's burden. AIMS To identify the profile of psychopathological symptoms in patients with PD and the impact imposed by this condition on the caregiver's burden. SUBJECTS Fifty patients with idiopathic PD seen consecutively at the Movement Disorder Outpatient Clinic at the Hospital of State University of Campinas, Brazil, and their 50 respective caregivers were studied. METHODS The 50 patients with PD were divided into three groups according to the respective psychiatric diagnosis received (depression: N = 17, dementia: N = 13 and non-depressed and non-demented: N = 20). We divided the caregivers into three groups according to the mental condition of their patients. To assess the mental condition of patients and the caregiver's burden, and to correlate those psychopathological features found with clinical features of PD, we applied the Neuropsychiatric Inventory (NPI). RESULTS Patients with dementia presented the highest NPI scores of psychopathological symptoms (26.4), followed by patients with depression (24.9). Non-depressed and non-demented patients revealed fewer symptoms (7.2). Caregivers' burden was found to be proportional to the degree of patients' symptomatology. CONCLUSION Patients with dementia presented more severe motor impairment and lower functionality, followed by patients with depression and those non-demented, non-depressed. Psychotic symptoms, agitation, aberrant motor behaviours and sleep disturbances were higher in dementia group. Neuropsychiatric disturbances correlated with caregiver's burden, which was highest in patients with dementia.
Collapse
Affiliation(s)
- Florindo Stella
- Biosciences Institute, Campus of Rio Claro, UNESP-Sao Paulo State University, Brazil.
| | | | | | | | | |
Collapse
|
263
|
Abstract
Psychotic symptoms are frequent and disabling in patients with Parkinson's disease (PD). Methodological issues in the epidemiology of PD associated psychosis (PDP) include differences in the symptoms assessed, the methods of assessment, and the selection of patients. Most studies are prospective clinic-based cross-sectional studies providing point prevalence rates in samples on dopaminergic treatment. Visual hallucinations are present in about one quarter to one third of the patients, auditory in up to 20%. Tactile/somatic, and olfactory hallucinations are usually not systematically sought. Minor phenomena such as sense of presence and visual illusions affect 17 to 72% of the patients, and delusions about 5%. Lifetime prevalence of visual hallucinations reaches approximately 50%. Prospective longitudinal cohort studies suggest that hallucinations persist and worsen in individual patients, and that their prevalence increases with time. A facilitating role of treatment on PDP is demonstrated at least for dopaminergic agonists, but there is no simple dose-effect relationship between dopaminergic treatment and the presence or severity of hallucinations. The main endogenous non-modifiable risk factor is cognitive impairment. Other associated factors include older age/longer duration of PD, disease severity, altered dream phenomena, daytime somnolence, and possibly depression and dysautonomia. PDP reduces quality of life in patients and increases caregiver distress, and is an independent risk factor for nursing home placement and development of dementia.
Collapse
|
264
|
Abstract
Several recent studies have shown that dementia is common in Parkinson's disease (PD), and that in some patients, cognitive impairment occurs even at the time of diagnosis. The point prevalence of dementia in PD is close to 30% and the incidence rate is increased 4-6 times as compared to controls. The cumulative prevalence is very high, at least 75% of PD patients who survive for more than 10 years will develop dementia. The mean time from onset of PD to dementia is approximately 10 years. However, there are considerable variations, and some patients develop dementia early in the disease course. Earlier onset of dementia is associated with more structural brain changes. The most established risk factors for early dementia are old age, severity of motor symptoms, in particular postural and gait disturbances, mild cognitive impairment and visual hallucinations. The genetic contributions to dementia are currently not clear and need to be explored in future studies.
Collapse
Affiliation(s)
- Dag Aarsland
- The Norwegian Centre for Movement Disorders/Psychiatric Clinic, Stavanger University Hospital, Stavanger, Norway.
| | | |
Collapse
|
265
|
Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A, Dubbioso R, Picillo M, Barone P, Santoro L. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 2009; 132:2350-5. [PMID: 19584099 PMCID: PMC2800383 DOI: 10.1093/brain/awp166] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2009] [Revised: 04/16/2009] [Accepted: 05/15/2009] [Indexed: 11/13/2022] Open
Abstract
Visual hallucinations (VHs) represent a frequent and disturbing complication of Parkinson's disease. Evidence suggests that VH can be related to central cholinergic dysfunction. Short-latency afferent inhibition (SAI) technique gives the opportunity to test an inhibitory cholinergic circuit in the human cerebral motor cortex. This inhibition of motor-evoked potentials can be observed when transcranial magnetic stimulation is delivered with a delay ranging from 2 to 8 ms, after a peripheral nerve afferent input has reached the somatosensory cortex. We applied SAI technique in 10 non-demented patients with Parkinson's disease with VHs, in 12 non-demented patients with Parkinson's disease without VHs (NVH-pts) and in 11 age-matched normal controls. All patients with Parkinson's disease underwent a battery of neuropsychological tests to assess frontal and visuospatial functions, memory and attention. SAI was significantly reduced in patients with VHs compared with controls and patients without VHs. Neuropsychological examination showed a mild cognitive impairment in 16 out of 22 patients with Parkinson's disease. In addition, we found that in our patients with VHs, performance of some tasks evaluating visuospatial functions and attentional/frontal lobe functions was significantly more impaired than in patients without VHs. SAI abnormalities, presence of VH and neuropsychological results strongly support the hypothesis of cholinergic dysfunction in some patients with Parkinson's disease, who will probably develop a dementia. A follow-up study of our patients is required to verify whether SAI abnormalities can predict a future severe cognitive decline. Moreover, SAI can also be very useful to follow-up the efficacy of anti-cholinesterase therapies.
Collapse
Affiliation(s)
- Fiore Manganelli
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Carmine Vitale
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
- 2 University Parthenope of Naples, Naples, Italy
- 3 Istituto di Diagnosi e Cura Hermitage Capodimonte, Naples, Italy
| | - Gabriella Santangelo
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
- 3 Istituto di Diagnosi e Cura Hermitage Capodimonte, Naples, Italy
- 4 Second University of Naples, Neuropsychology Laboratory, Department of Psychology, Naples, Italy
| | - Chiara Pisciotta
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Rosa Iodice
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Autilia Cozzolino
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Raffaele Dubbioso
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Marina Picillo
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Paolo Barone
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| | - Lucio Santoro
- 1 Department of Neurological Sciences, University Federico II of Naples, Naples, Italy
| |
Collapse
|
266
|
Sausenthaler S, Loebel T, Linseisen J, Nagel G, Magnussen H, Heinrich J. Vitamin E intake in relation to allergic sensitization and IgE serum concentration. Cent Eur J Public Health 2009; 17:79-85. [PMID: 19662825 DOI: 10.21101/cejph.a3521] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND A protective role of dietary vitamin E intake on disorders related to the immune system, such as allergic diseases, has been suggested. However, results from epidemiological studies are conflicting. OBJECTIVES The aim of present study was to analyze whether dietary vitamin E intake is related to the prevalence of allergic sensitization and total serum IgE concentrations in adult subjects. METHODS The present study population consisted of 366 adults aged 29 to 54 years participating in the German centers of the European Community Respiratory Health Survey (ECRHS) II, Erfurt and Hamburg. A validated food frequency questionnaire was used to gather information on dietary vitamin E intake. Total serum IgE concentrations and specific IgE to common allergens were analyzed by using the Pharmacia CAP System. Allergic sensitization was defined as specific serum IgE concentration > or = 0.35 kU/l. RESULTS The risk for allergic sensitization was substantially decreased in the middle quartiles (aOR: 0.42; 95% CI: 0.22-0.81) and the highest quartile (aOR: 0.22; 95% CI: 0.08-0.60) of total dietary vitamin E intake, after adjustment for potential confounders. Total serum IgE concentration was not statistically significantly associated with dietary vitamin E intake. CONCLUSIONS The findings of this study suggest that dietary vitamin E intake might play a protective role in the development of allergic sensitization.
Collapse
Affiliation(s)
- Stefanie Sausenthaler
- Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology, Neuherberg, Germany.
| | | | | | | | | | | |
Collapse
|
267
|
Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. J Neurol 2009; 257:217-23. [PMID: 19705051 DOI: 10.1007/s00415-009-5297-x] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2009] [Revised: 07/12/2009] [Accepted: 08/12/2009] [Indexed: 10/20/2022]
Abstract
Apathy is a common behavioural problem in Parkinson's disease (PD), with important clinical consequences for patients and their families. However, little is known about apathy in early PD. We examined the frequency and clinical characteristics of apathy in 175 nondemented, drug-naïve patients with newly diagnosed PD and 165 control subjects matched for age, sex and education level in Western and Southern Norway. All participants underwent a comprehensive neurological, psychiatric and neuropsychological evaluation. Apathy was diagnosed based on Neuropsychiatric Inventory assessment and recently proposed consensus criteria. Apathy was found in 22.9% of the PD patients, of whom 37.5% had significant depressive symptoms, whereas none of the control subjects were apathetic. Apathy was significantly associated with male gender, higher depression scores and more severe motor symptoms, but was not associated with greater cognitive impairment. When excluding patients with significant depressive symptoms, apathy remained significantly associated with motor severity. Approximately 50% of the caregivers of patients with apathy reported the apathetic behaviour to be at least moderately distressing. The association between apathy and motor severity in our PD cohort suggests a common underlying pathophysiological mechanism. Future studies should explore the longitudinal effect of dopamine replacement therapy on apathetic behaviour in early PD. The relationship between apathy and male gender needs further study to be fully evaluated.
Collapse
|
268
|
Abstract
Parkinson's disease is the second most common neurodegenerative illness diagnosed in the United States. Dementia is recognized as a common component of advanced Parkinson's disease (PD). In patients with early PD, cognitive changes occur and primarily reflect impairment in executive function. It is unknown if the early cognitive changes detected on neuropsychological testing in Parkinson's disease are predictive of the subsequent development of Parkinson's disease with dementia (PDD). Many patients with PD develop dementia characterized by a wide range of cognitive deficits distinct from those seen in Alzheimer's disease (AD). Neuropsychiatric problems frequently accompany PDD. This chapter reviews the epidemiology, clinical characteristics of early and late cognitive changes, pathology, neuroimaging, diagnosis, and treatment of PDD.
Collapse
|
269
|
Hasnain M, Vieweg WVR, Baron MS, Beatty-Brooks M, Fernandez A, Pandurangi AK. Pharmacological management of psychosis in elderly patients with parkinsonism. Am J Med 2009; 122:614-22. [PMID: 19559160 DOI: 10.1016/j.amjmed.2009.01.025] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2008] [Revised: 11/26/2008] [Accepted: 01/29/2009] [Indexed: 11/30/2022]
Abstract
Parkinsonism is a characteristic feature of Parkinson's disease and dementia with Lewy bodies and is commonly seen in Alzheimer's disease. Psychosis commonly appears during the course of these illnesses. Treatment of parkinsonism with antiparkinsonian medications constitutes an additional risk factor for the appearance or worsening of psychosis. Conversely, treatment of psychosis with antipsychotic drugs in patients with parkinsonism might worsen the underlying movement disorder, especially in the elderly. In this article, we review parkinsonian conditions in the elderly and offer guidelines to assess and manage comorbid psychosis. We focus on the pharmacologic management of psychosis with atypical antipsychotic medications and briefly review the role of acetylcholinesterase inhibitors.
Collapse
Affiliation(s)
- Mehrul Hasnain
- Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, Stephenville, Newfoundland, Canada.
| | | | | | | | | | | |
Collapse
|
270
|
Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol 2009; 9:23. [PMID: 19515253 PMCID: PMC2704166 DOI: 10.1186/1471-2377-9-23] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2008] [Accepted: 06/10/2009] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Psychosis is rare in untreated patients with Parkinson's disease (PD) but the prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the psychogenic potential of different dopaminergic drugs had been performed. METHODS Eighty PD patients with psychotic episodes were compared to an age-matched control group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study. RESULTS We found a positive correlation between psychotic episodes and dementia, number of concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio, levodopa the lowest. An adjusted logistic regression model confirmed the strong association with psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and 0.11, respectively). CONCLUSION The analysis indicates that dementia and concomitant medication are factors in PD associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly different associations with psychotic symptoms.
Collapse
Affiliation(s)
- Daniel Ecker
- Department of Neurology, University of Ulm, 89081 Ulm, Germany
- Current address: Focus Clinical Drug Development, Neuss, Germany
| | | | - Jan Kassubek
- Department of Neurology, University of Ulm, 89081 Ulm, Germany
| | - Michael Sabolek
- Department of Neurology, University of Ulm, 89081 Ulm, Germany
- Current address: Department of Neurology, EMA-University of Greifswald, 17475 Greifswald, Germany
| |
Collapse
|
271
|
Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics 2009; 9:56-61. [PMID: 19604326 DOI: 10.1111/j.1479-8301.2009.00292.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Dementia with Lewy bodies (DLB) is a common type of dementia. It is difficult to make an initial diagnosis of DLB because of a variety of early symptoms, including psychosis-like and depressive states. In this study, we examined the characteristic depressive symptoms of the prestage of DLB and the efficacy and safety of somatotherapy for depression accompanying DLB. METHODS Subjects in the study were 167 consecutive clinical cases aged 50 years or more, hospitalized at Tsukuba University Hospital from December 2002 to September 2007. At the time of admission, patients were diagnosed with certain types of mood disorders according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision. For each subject, a series of neuropsychological tests, along with a standard psychiatric and neurological assessment and biological examinations, were conducted. Using the data from these exams, we diagnosed probable and possible DLB according to the criteria for dementia with Lewy bodies established by McKeith et al. 1 We compared patients' depressive symptoms according to the Hamilton Depression Scale, and distinguished between patients with depression associated with DLB and those with other mood disorders. 2 We also examined the efficacy and safety of somatotherapy (electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS)) for patients with drug therapy-resistant depression associated with DLB. RESULTS 1 The characteristic symptoms of patients with DLB were classified into two groups: psychotic and non-psychotic. The former consisted of patients with states such as delusion and agitation, and the latter included patients exhibiting psychomotor retardation, loss of insight and hypochondriasis. 2 Eight DLB patients with therapy-resistant depression underwent ECT. After ECT, significant improvement was observed, with no remarkable safety hazards. Six patients with drug therapy-resistant DLB underwent TMS. TMS appears to be an effective, safe remedy for this kind of patient. CONCLUSIONS A total of 13.8% of patients came to be re-diagnosed as having DLB as a consequence of a thorough examination after admission. Patients with depression associated with DLB were classified into psychotic and non-psychotic clusters. ECT and TMS are effective and safe therapeutic tools for drug therapy-resistant depression observed in DLB patients.
Collapse
Affiliation(s)
- Sho Takahashi
- Clinical Neuroscience, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
| | | | | | | |
Collapse
|
272
|
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2009; 23:1889-96. [PMID: 18709682 DOI: 10.1002/mds.22246] [Citation(s) in RCA: 146] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
A cross-sectional study of the profile of psychiatric symptoms and their relationships to medications, executive performance, and excessive daytime somnolence (EDS) was conducted on 1351 consecutive Parkinson's disease patients without dementia (PD-ND). Ratings were: neuropsychiatric inventory (NPI); hospital anxiety and depression scale (HADS); executive performance (semantic, phonemic, and alternating verbal fluencies); and the Epworth sleepiness scale (ESS). Eighty-seven percent of the subjects reported at least one psychiatric symptom. The most common were depression (70%), anxiety (69%), apathy (48%), and irritability (47%). Fifty percent of the patients had HADS-depression scores ranging from possible (8-10; 22%) to probable (>or=11; 28%) depression. Executive impairment was found in 41% and EDS in 26% of subjects. All considered variables were significantly more common with longer duration and more severe disease. Only depression appeared to be influenced by type of medication, being less prevalent among patients treated with DAs. Five NPI clusters were identified among patients scoring >or=1 on the NPI (87.3%): patients exhibiting predominantly apathy (12.7%), psychosis (3%), depression (13%), anxiety (15.6%), and "low-total NPI" (43.2%). Neuropsychiatric symptoms are common in nondemented PD patients suggesting that they are an integral part of PD from the beginning of the disease and appears more related to disease progression than to the type of antiparkinsonian medication. Apathy emerged as an independent construct in PD-ND, indicating the need to address specific therapeutical approaches targeted toward this particular symptom.
Collapse
Affiliation(s)
- Jaime Kulisevsky
- Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Spain.
| | | | | | | | | | | |
Collapse
|
273
|
Abstract
Dementia affects approximately one-third of all patients with Parkinson's disease. Currently there is no treatment to halt or reverse the disease progression. Symptomatic treatment approaches are based on substituting neurotransmitter deficits or ameliorating associated behavioral symptoms. The most prominent deficits are cholinergic, and treatment with cholinesterase inhibitors (ChE-I) has been shown to provide some benefits in cognitive and behavioral symptoms without undue worsening in motor symptoms. Based on a large, randomized, placebo controlled trial, the ChE-I rivastigmine has been approved for the treatment of dementia associated with PD.
Collapse
Affiliation(s)
- M Emre
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
| |
Collapse
|
274
|
Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009; 194:212-9. [PMID: 19252147 DOI: 10.1192/bjp.bp.108.049619] [Citation(s) in RCA: 229] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Behavioural and psychological symptoms of dementia (BPSD) are major contributors to the burden of dementia. AIMS To describe the prevalence, correlates and course of BPSD in the population of England and Wales. METHOD The prevalence of 12 symptoms was estimated in 587 participants with dementia and 2050 participants without dementia as part of a population-based longitudinal study of ageing. The effect of risk factors and the factor structure were estimated using 1782 interviews provided by participants with dementia throughout the study. RESULTS Each symptom apart from sleeping problems was more common in the population with dementia. The co-occurrence of the symptoms was explained by a four-factor solution, corresponding to psychosis/apathy, depression/anxiety, irritability/persecution and wandering/sleep problems. Psychosis occurred more frequently with declining cognition. Anxiety and depression were more common in younger individuals and in those with poor self-reported health. Persistence varied between symptoms. CONCLUSIONS Behavioural and psychological symptoms of dementia affect nearly all people with dementia. Symptoms co-occur, and the symptoms that affected individuals experience are related to their socio-demographic and clinical characteristics.
Collapse
Affiliation(s)
- George M Savva
- Department of Public Health and Primary Care, University of Cambridge, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 0SR, UK.
| | | | | | | | | | | | | |
Collapse
|
275
|
Predictors of caregiver burden in partners of patients with Parkinson’s disease. Neurol Sci 2009; 30:171-4. [DOI: 10.1007/s10072-009-0024-z] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2008] [Accepted: 12/24/2008] [Indexed: 10/21/2022]
|
276
|
Ganguli M. Depression, cognitive impairment and dementia: Why should clinicians care about the web of causation? Indian J Psychiatry 2009; 51 Suppl 1:S29-34. [PMID: 21416013 PMCID: PMC3038544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Depression, cognitive impairment and dementia are all common in older adults. The relationship between them is bi-directional and complex. The literature on the subject is growing and fascinating but also riddled with apparent inconsistencies. This brief review attempts to clarify and integrate information from clinical, laboratory, and community studies and to draw some inferences of potential relevance to clinicians.
Collapse
Affiliation(s)
- Mary Ganguli
- Professor of Psychiatry, Neurology, and Epidemiology, University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA 15208, USA
| |
Collapse
|
277
|
|
278
|
Current world literature. Trauma and rehabilitation. Curr Opin Neurol 2008; 21:762-4. [PMID: 18989123 DOI: 10.1097/wco.0b013e32831cbb85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
279
|
Reijnders JSAM, Ehrt U, Lousberg R, Aarsland D, Leentjens AFG. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2008; 15:379-82. [PMID: 18977165 DOI: 10.1016/j.parkreldis.2008.09.003] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2008] [Revised: 09/11/2008] [Accepted: 09/18/2008] [Indexed: 01/17/2023]
Abstract
BACKGROUND In Parkinson's disease (PD) it has been suggested that various motor subtypes are also characterized by a different prevalence and severity of specific non-motor symptoms such as cognitive deterioration, depression, apathy and hallucinations. The aim of this study was to investigate the association between motor subtypes and psychopathology in PD. METHODS An exploratory and confirmatory cluster analysis of motor and psychopathological symptoms was performed with a randomized sample of 173 patients each, stemming from two research databases: one from Stavanger University Hospital and one from Maastricht University Hospital. These databases contained data of standardized assessments of patients with the Unified Parkinson's Disease Rating Scale, the Montgomery-Asberg Depression Rating Scale, and the Mini-Mental State Examination. RESULTS PD patients can be accurately and reliably classified into four different subtypes: rapid disease progression subtype, young-onset subtype, non-tremor-dominant subtype with psychopathology and a tremor-dominant subtype. Cognitive deterioration, depressive and apathetic symptoms, and hallucinations all cluster within the non-tremor-dominant motor subtype, that is characterized by hypokinesia, rigidity, postural instability and gait disorder. CONCLUSIONS This study shows that non-tremor-dominant PD is associated with cognitive deterioration, depression, apathy, and hallucinations, which has implications for future research into the pathophysiology of psychopathology in PD.
Collapse
Affiliation(s)
- J S A M Reijnders
- Department of Psychiatry, Maastricht University Hospital, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands
| | | | | | | | | |
Collapse
|
280
|
Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2008; 15:295-9. [PMID: 18801696 DOI: 10.1016/j.parkreldis.2008.07.006] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2008] [Revised: 06/15/2008] [Accepted: 07/25/2008] [Indexed: 12/20/2022]
Abstract
The objective of this study was to examine the prevalence and clinical correlates of apathy in a population-based sample of patients with Parkinson's disease (PD) and to assess whether apathy may present as a primary behavioural disturbance independent from depression and cognitive impairment. A total of 232 patients derived from an epidemiological study of PD in Rogaland county, Western Norway, completed a comprehensive evaluation of motor, cognitive, and depressive symptoms. Apathy was assessed with the motivation/initiative item of the Unified Parkinson's Disease Rating Scale. The majority of the population had mild to moderate PD with mean disease duration of 9.1+/-5.7 years. Apathy was diagnosed in 38% of the 232 patients. In 11% of the total sample apathy coexisted with depression and dementia, whereas 10% had apathy and depression without dementia, 6.5% apathy and dementia without depression, and 9% were apathetic without dementia or depression (data missing in 1.5% patients). Apathy was significantly associated with higher depression scores, lower cognitive functioning, and more severe motor symptoms. When excluding patients with depression, dementia, cognitive impairment with no dementia (population-based age- and education-corrected norms for the Mini-Mental State Examination), and those using psychotropic medication, 5% of the 232 patients had apathy. In conclusion, our study shows that apathy is common in the general PD population, may present as an independent behavioural disorder, and suggests that apathy in PD may be related to dysfunction of the nigro-striatal pathway or that brain pathology underlying apathy and progression of motor symptoms develops in parallel.
Collapse
|
281
|
Holt RJ. Estimate of point prevalence of Parkinson's disease induced psychosis in the United States. Mov Disord 2008; 23:1788-9. [DOI: 10.1002/mds.22195] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
282
|
Perceived unmet needs for health care among Parkinson's Society of New Zealand members with Parkinson's disease. Parkinsonism Relat Disord 2008; 14:495-500. [DOI: 10.1016/j.parkreldis.2007.11.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2007] [Revised: 11/12/2007] [Accepted: 11/12/2007] [Indexed: 11/20/2022]
|
283
|
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33:957-70. [PMID: 17637610 PMCID: PMC2553721 DOI: 10.1038/sj.npp.1301492] [Citation(s) in RCA: 218] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6-1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.
Collapse
Affiliation(s)
- Dilip V Jeste
- Department of Psychiatry and Neurosciences, University of California, San Diego, CA 92161, USA.
| | | | | | | | | | | | | | | |
Collapse
|
284
|
Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008; 13:18-25. [PMID: 18323763 DOI: 10.1017/s1092852900017284] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Psychosis in Parkinson's disease refers to a combination of hallucinations and delusions occurring with a clear sensorium and a chronic course. Hallucinations may involve several sensory modalities. Complex visual hallucinations are the most common type. "Minor" hallucinatory phenomena are frequently present and include visual illusions, passage hallucinations, and sense of presence. Insight may be lost in patients with cognitive impairment. Delusions of a paranoid type are more rare than hallucinations. Both hallucinations and delusions are more frequent in Parkinson's disease patients with dementia. Pathogenesis involves complex and probably multifactorial mechanisms, including pharmacologic (dopaminergic treatment and others) and disease-related factors.
Collapse
|
285
|
Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008; 23:837-44. [PMID: 18307261 DOI: 10.1002/mds.21956] [Citation(s) in RCA: 1429] [Impact Index Per Article: 89.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Mariese A Hely
- Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia.
| | | | | | | | | |
Collapse
|
286
|
Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2008; 22:2314-24. [PMID: 18098298 DOI: 10.1002/mds.21844] [Citation(s) in RCA: 728] [Impact Index Per Article: 45.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time-consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD-D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD-D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence-based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies.
Collapse
Affiliation(s)
- Bruno Dubois
- INSERM-UPMC UMRS 610, Federation of Neurology, AP-HP, Salpêtrière Hospital; Université Paris6, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
287
|
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2008; 22:1689-707; quiz 1837. [PMID: 17542011 DOI: 10.1002/mds.21507] [Citation(s) in RCA: 1999] [Impact Index Per Article: 124.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Dementia has been increasingly more recognized to be a common feature in patients with Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of dementia associated with PD (PD-D), however, have been lacking. A Task Force, organized by the Movement Disorder Study, was charged with the development of clinical diagnostic criteria for PD-D. The Task Force members were assigned to sub-committees and performed a systematic review of the literature, based on pre-defined selection criteria, in order to identify the epidemiological, clinical, auxillary, and pathological features of PD-D. Clinical diagnostic criteria were then developed based on these findings and group consensus. The incidence of dementia in PD is increased up to six times, point-prevelance is close to 30%, older age and akinetic-rigid form are associated with higher risk. PD-D is characterized by impairment in attention, memory, executive and visuo-spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent. There are no specific ancillary investigations for the diagnosis; the main pathological correlate is Lewy body-type degeneration in cerebral cortex and limbic structures. Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD-D are proposed.
Collapse
Affiliation(s)
- Murat Emre
- Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
288
|
Aarsland D, Janvin C. Clinical aspects of Parkinson dementia. HANDBOOK OF CLINICAL NEUROLOGY 2008; 89:303-306. [PMID: 18631754 DOI: 10.1016/s0072-9752(07)01228-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- Dag Aarsland
- Centre for Clinical Neuroscience Research, Stavanger University Hospital, Stavanger, Norway.
| | | |
Collapse
|
289
|
Carod-Artal FJ, Martínez-Martin P, Kummer W, da Silveira Ribeiro L. Psychometric attributes of the SCOPA-COG Brazilian version. Mov Disord 2008; 23:81-7. [DOI: 10.1002/mds.21769] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
290
|
Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24:20-7. [PMID: 17496417 DOI: 10.1159/000102568] [Citation(s) in RCA: 143] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/06/2007] [Indexed: 01/25/2023] Open
Abstract
The efficacy of memantine in Alzheimer's disease (AD) has been investigated in multiple randomised, placebo-controlled phase III trials. Recently, the indication label for memantine in Europe was extended to cover patients with moderate to severe AD, i.e. Mini-Mental State Exam total scores below 20. The efficacy data for memantine in this patient subgroup has been summarised by a meta-analysis of 1,826 patients in six trials. Efficacy was assessed using measures of global status (Clinician's Interview-Based Impression of Change Plus Caregiver Input), cognition (Alzheimer's Disease Assessment Scale - Cognitive Subscale, or Severe Impairment Battery), function (Alzheimer's Disease Cooperative Study Activities of Daily Living 19- or 23-item scale), and behaviour (Neuropsychiatric Inventory). Results (without replacement of missing values) showed statistically significant effects for memantine (vs. placebo) in each domain. Memantine was well tolerated, and the overall incidence rates of adverse events were comparable to placebo. This meta-analysis supports memantine's clinically relevant efficacy in patients with moderate to severe AD.
Collapse
|
291
|
Benarroch EE, Schmeichel AM, Sandroni P, Parisi JE, Low PA. Rostral raphe involvement in Lewy body dementia and multiple system atrophy. Acta Neuropathol 2007; 114:213-20. [PMID: 17639427 DOI: 10.1007/s00401-007-0260-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2007] [Revised: 06/05/2007] [Accepted: 06/21/2007] [Indexed: 11/26/2022]
Abstract
Depression is a feature of both Lewy body disorders and multiple system atrophy (MSA). Since serotonergic neurons of the rostral raphe have been implicated in depression, we sought to determine whether there is a differential involvement of these neurons in cases with clinically diagnosed dementia with Lewy bodies (DLB) or MSA. We studied the brainstem obtained at autopsy from fourteen patients with diagnosis of DLB and pathological limbic or neocortical stage Lewy body disease, 13 patients with clinical and neuropathological diagnosis of MSA, and 12 controls with no history of neurologic disease. The clinical features of these patients were analyzed retrospectively by reviewing their medical records. Serial sections were immunostained for tryptophan hydroxylase (TrOH) and alpha-synuclein and cell counts were performed in the dorsal raphe (DR), median raphe (MR) and medullary raphe nuclei. There was loss of serotonergic cells in both the DR and MR in DLB compared to control cases: For the DR, the number of cells/section were 53 +/- 6 in DLB versus 159 +/- 13 (P < 0.001) respectively, and for the MR 70 +/- 11 in DLB versus 173 +/- 23 (P < 0.001) respectively. In contrast, these cells were relatively preserved in MSA. The caudal raphe groups were affected both in MSA and in DLB. There is a differential involvement of raphe neurons in DLB and MSA. Although loss of rostral raphe neurons may contribute to depression in DLB, this appears to be less likely in MSA. Factors other than the neurochemical phenotype determine neuronal vulnerability in MSA.
Collapse
Affiliation(s)
- E E Benarroch
- Department of Neurology, Mayo Clinic, 811 Guggenheim Building, 200 First Street SW, Rochester, MN 55905, USA.
| | | | | | | | | |
Collapse
|
292
|
Abstract
This article provides an update on depression and apathy in Parkinson's disease (PD), both of which are common but often misunderstood. The diagnosis of depression in PD can be challenging and we still do not have solid evidence on which to base our treatment decisions. Apathy is most commonly seen in the setting of dementia or depression but emerging evidence suggests that it may be a core feature of PD. There are conflicting reports about the effects of deep brain stimulation (DBS) on mood and apathy, but studies suggest that at least some patients may develop depression and apathy after the procedure. Although we are making strides toward a better understanding of depression and apathy in PD, it is clear that more research is needed about these non-motor features.
Collapse
Affiliation(s)
- Irene Hegeman Richard
- Department of Neurology, University of Rochester School of Medicine, Mt. Hope Professional Building, 1351 Mt. Hope Avenue, Suite 100, Rochester, NY 14620-3917, USA.
| |
Collapse
|
293
|
McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord 2007; 14:37-42. [PMID: 17627863 DOI: 10.1016/j.parkreldis.2007.05.009] [Citation(s) in RCA: 118] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2007] [Revised: 05/12/2007] [Accepted: 05/22/2007] [Indexed: 11/20/2022]
Abstract
Neuropsychiatric problems are common in Parkinson's disease (PD) but there is little information regarding how they impact on quality of life. PD patients without dementia (49) were assessed for low mood/depression, fatigue, apathy, sleep problems and hallucinations. Measures of quality of life and motor function were also obtained. Over 77% of the patients reported symptoms consistent with one or more neuropsychiatric problems. Low mood/depression, anxiety and the presence of hallucinations predicted poorer quality of life after controlling for motor symptoms. Additional to the motor symptoms, we found that specific neuropsychiatric problems may impact on quality of life for PD patients.
Collapse
Affiliation(s)
- A McKinlay
- Psychology Department, University of Canterbury, PO Box 1485, Private Bag 4800, Christchurch, Canterbury 8004, New Zealand.
| | | | | | | | | | | |
Collapse
|
294
|
Leroi I, Burns A. Behavioural and psychological symptoms of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78:2-3. [PMID: 16954135 PMCID: PMC2117783 DOI: 10.1136/jnnp.2006.101162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Assessment of behavioural and psychological symptoms is important in brain disorders
Collapse
|